MN
Manuel Navas Piper Sandler Latest Price Targets & Analyst Ratings
Main Sector
Financials
Ratings Past Year
39
Avg Return
Past Year
Past Year
3.8%
Success Rate
Past Year
Past Year
0
%
Rating Distribution
Past 3 Months
Positive
55.6%
Neutral
44.4%
Negative
0%
Past Week
Past Month
Past 3 Months
Past 6 Months
Past Year
All Time
Positive
Neutral
Negative
Large Cap
$10B to $200B
Mid Cap
$2B to $10B
Small Cap
$250M to $2B
Micro Cap
Under $250M
Financials
Healthcare
Financials
Banks - Diversified
Banks - Regional
Healthcare
Biotechnology
| Stock | Rating | Price Target |
Upside Downside |
Ratings 3 Months |
Avg Return 1 Year |
Success Rate 1 Year | Date | |
|---|---|---|---|---|---|---|---|---|
|
Overweight
Assumed
| $66 |
7%
upside
| 1 | +1.2% |
0
%
| 12 Mar ‘26 1 month ago |
|
|
|
Overweight
Assumed
| $107 |
8%
upside
| 1 | +2.4% |
0
%
| 12 Mar ‘26 1 month ago |
|
|
|
Overweight
Assumed
| $82 |
6%
upside
| 1 | +0.9% |
0
%
| 12 Mar ‘26 1 month ago |
|
|
|
Overweight
Reiterated
| $22 |
7%
upside
| 1 | +9.5% |
0
%
| 3 Feb ‘26 2 months ago |
|
|
|
Neutral
Reiterated
| $36 |
2%
upside
| 2 | – |
–
| 2 Feb ‘26 2 months ago |
|
|
|
Neutral
Reiterated
| $24 |
3%
upside
| 2 | – |
–
| 30 Jan ‘26 2 months ago |
|
|
|
Neutral
Maintained
| $67 |
5%
downside
| 2 | +1.6% |
0
%
| 29 Jan ‘26 2 months ago |
|
|
|
Neutral
Maintained
| $130 |
2%
upside
| 1 | – |
–
| 23 Jan ‘26 2 months ago |
|
|
|
Overweight
Reiterated
| $21 |
17%
upside
| 1 | +8% |
0
%
| 22 Jan ‘26 2 months ago |
|